Products - Autoimmune - Nephrology - Primary membranous nephropathy

Primary membranous nephropathy

Contact our Autoimmune Product Team for further details and information

Disease information

Primary membranous nephropathy (pMN) is a chronic disease of the renal glomeruli that results in impairment of the renal functions. The disease bears an autoimmune etiology. It is instigated by the autoantibodies that are directed against glycoprotein phospholipase A2 receptor (PLA2R) and thrombospondin type 1 domain containing protein 7A (THSD7A). These antibodies react against the podocytes surrounding the renal glomeruli causing them significant damage. The result is leakage of the proteins in the urine (proteinuria).

Primary membranous nephropathy (pMN) is a leading cause of nephrotic syndrome in adults. Peak incidence is seen in light-complexioned males over 40 years of age. In women however, lupus nephritis is always suspected and considered with pMN. Primary membranous nephropathy is very rare in children.

Secondary pMN
Primary membranous nephropathy has to be differentiated from secondary pMN which is seen usually after infections, drug therapy and toxins. Early diagnosis and prompt treatment improves disease prognosis with respect to nephrotic syndrome and hypertonicity.

Diagnostic Guidelines

Diagnosis of pMN follows a routine protocol for kidney puncture, histological and electron microscopic examination of the kidney tissue. However, serological testing has helped make the process faster and less irritating for the patient. The characteristic antibodies against PLA2R and THSD7A can be found in the patients with pMN and are strong indicators for the disease. Especially those against PLA2R are found in about 80% of the cases.

Methods to detect the antibodies

Methods to detect these antibodies include

  • IFA
  • ELISA
  • ChLIA

IFA allows for a semi-quantitative determination of the antibodies whereas ELISA and ChLIA allow reliable quantification. The antibody titers hold a high predictive value and they can also be used to monitor therapy success or risk of relapse as these usually vary in accordance with the clinical picture.

The anti-THSD7A IFA is an excellent supplement to the serological testing for anti-PLA2R. Even in patients negative for PLA2R antibodies, additional screening is done for anti-THSD7A to rule out any possibility of the disease.

Primary membranous nephropathy products

The individual product regulatory statements may vary, please refer to the instructions for use for more information.

wdt_ID Method Parameter Substrate Species/ Antigen
708 IFA antibodies against phospholipase A2 receptor
(PLA2R ab control)
709 ELISA phospholipase A2 receptor
(PLA2R)
antigen-coated
microplate wells
recombinant, human c-DNA
expressed in human cell line
710 ChLIA control set
phospholipase A2 receptor
(PLA2R)
711 ChLIA phospholipase A2 receptor
(PLA2R)
712 IFA antibodies against thrombospondin type-1 domain-containing protein 7A
(THSD7A ab control)
713 IFA Membranous Nephropathy Mosaic 1
phospholipase A2 receptor (PLA2R)
Thrombospondin type-1 domain-containing
protein 7A (THSD7A)
3 BIOCHIPs per field:
transfected cells
transfected cells
control transfection
EU 90
EU 90
EU 90
714 IFA phospholipase A2 receptor (PLA2R) transfected cells
control transfection
(2 BIOCHIPs per field)
EU 90
EU 90
715 IFA phospholipase A2 receptor (PLA2R)
EUROPattern
transfected cells
control transfection
(2 BIOCHIPs per field)
EU 90
EU 90
716 IFA Thrombospondin type-1 domain-
containing protein 7A (THSD7A)
transfected cells
control transfection
(2 BIOCHIPs per field)
EU 90
EU 90
717
Method Parameter Substrate Species/ Antigen
For product information, please contact the EUROIMMUN Sales Team

Product Catalog

Download our full EUROIMMUN US 2022 Product Catalog (PDF 12MB)

Download PDF

2022 EUROIMMUN US

Privacy Policy | Sitemap